Gouldson P, Calandra B, Legoux P, Kernéis A, Rinaldi-Carmona M, Barth F, Le Fur G, Ferrara P, Shire D (2000). „Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor”. European Journal of Pharmacology. 401 (1): 17—25. PMID10915832. doi:10.1016/S0014-2999(00)00439-8.
Nackley AG, Makriyannis A, Hohmann AG (2003). „Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation”. Neuroscience. 119 (3): 747—57. PMID12809695. doi:10.1016/S0306-4522(03)00126-X.
Páldy E, Bereczki E, Sántha M, Wenger T, Borsodi A, Zimmer A, Benyhe S (2008). „CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain”. Neurochemistry International. 53 (6-8): 309—16. PMID18804501. doi:10.1016/j.neuint.2008.08.005.
Lay L, Angus JA, Wright CE (2000). „Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse”. European Journal of Pharmacology. 391 (1-2): 151—61. PMID10720647. doi:10.1016/S0014-2999(00)00062-5.
Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI (2010). „The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat”. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22 (6): 694—e206. PMID20132133. doi:10.1111/j.1365-2982.2009.01466.x.
Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL (1998). „SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor”. The Journal of Pharmacology and Experimental Therapeutics. 284 (2): 644—50. PMID9454810.
Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, Barth F, le Fur G, Casellas P (1999). „SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist”. The Journal of Pharmacology and Experimental Therapeutics. 288 (2): 582—9. PMID9918562.
Gouldson P, Calandra B, Legoux P, Kernéis A, Rinaldi-Carmona M, Barth F, Le Fur G, Ferrara P, Shire D (2000). „Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor”. European Journal of Pharmacology. 401 (1): 17—25. PMID10915832. doi:10.1016/S0014-2999(00)00439-8.
Nackley AG, Makriyannis A, Hohmann AG (2003). „Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation”. Neuroscience. 119 (3): 747—57. PMID12809695. doi:10.1016/S0306-4522(03)00126-X.
Páldy E, Bereczki E, Sántha M, Wenger T, Borsodi A, Zimmer A, Benyhe S (2008). „CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain”. Neurochemistry International. 53 (6-8): 309—16. PMID18804501. doi:10.1016/j.neuint.2008.08.005.
Lay L, Angus JA, Wright CE (2000). „Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse”. European Journal of Pharmacology. 391 (1-2): 151—61. PMID10720647. doi:10.1016/S0014-2999(00)00062-5.
Germanò MP, D'Angelo V, Mondello MR, Pergolizzi S, Capasso F, Capasso R, Izzo AA, Mascolo N, De Pasquale R (2001). „Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats”. Naunyn-Schmiedeberg's Archives of Pharmacology. 363 (2): 241—4. PMID11218077.
Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI (2010). „The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat”. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 22 (6): 694—e206. PMID20132133. doi:10.1111/j.1365-2982.2009.01466.x.